- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
2022.
-
- Jun.23.2022 Management / Finance
- Announcement on Disposal of Treasury Shares as Restricted Stock-based Remuneration
-
- Jun.07.2022 R & D
- Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
-
- Jun.07.2022 R & D
- Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
-
- May.30.2022 R & D
- U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
-
- May.26.2022 R & D
- Two Combination Treatments of Opdivo + Yervoy and Opdivo + Chemotherapy Approved in Japan for First-line Treatment of Unresectable Advanced or Recurrent Esophageal Cancer
-
- May.19.2022 R & D
- Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma
-
- May.18.2022 R & D
- Opdivo® Intravenous Infusion Approved for the Treatment of Previously Untreated or Advanced Renal Cell Carcinoma in Combination with Cabozantinib in Taiwan
-
- May.11.2022 Management / Finance
- Announcement on Financial Results for FY2021
-
- May.11.2022 Management / Finance
- Notice regarding Differences in the Non-consolidated Financial Results between the Fiscal Year Ended March 31, 2022 and the Previous Fiscal Year
-
- May.11.2022 Corporate
- Notice regarding Partial Amendments to the Articles of Incorporation
-
- May.11.2022 Corporate
- Announcement on the Revision of Remuneration System for Members of the Board of Directors
-
- Apr.28.2022 Management / Finance
- Ono Announces Completion of Cancellation of Treasury Stock
-
- Apr.25.2022 R & D
- ONO Submits Supplemental Application for Approval of Opdivo® (Nivolumab) in Combination with Chemotherapy to Expand its Use as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Japan
-
- Apr.19.2022 Licensing
- Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery
-
- Apr.13.2022 R & D
- FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
-
- Apr.12.2022 R & D
- Opdivo® Intravenous Infusion Approved in Taiwan for the Adjuvant Treatment of Urothelial Carcinoma
-
- Apr.06.2022 R & D
- Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%
-
- Apr.06.2022 R & D
- Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%
-
- Apr.06.2022 R & D
- Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
-
- Apr.06.2022 Corporate
- Announcement on Changes of the Board of Directors and Corporate Officers
-
- Apr.06.2022 Management / Finance
- Notice regarding Partial Amendments to the Retirement of Treasury Shares
-
- Apr.01.2022 Corporate
- Notice concerning the Establishment of Ono Pharma UD Co., Ltd.
-
- Apr.01.2022 Corporate
- Initiation of Providing "Fukusapo", an Adverse Drug Reaction Management Supporting Tool for Patients Receiving Treatment with Immune Checkpoint Inhibitors
-
- Mar.31.2022 Licensing
- ONO Enters into a Development and License Agreement with Numab
-
- Mar.30.2022 Licensing
- ONO Enters into Collaboration Agreement with Iktos
-
- Mar.30.2022 R & D
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
-
- Mar.28.2022 R & D
- ONO Receives Supplemental Approval of Opdivo® (Nivolumab) for Adjuvant Treatment of Urothelial Carcinoma in Japan
-
- Mar.22.2022 R & D
- U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma
-
- Mar.18.2022 Corporate
- Notice regarding the Reorganization of Research Bases
-
- Mar.15.2022 Sustainability
- Humanitarian Assistance in Ukraine and its Surrounding Areas
-
- Mar.07.2022 R & D
- U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
-
- Mar.01.2022 R & D
- U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
-
- Feb.28.2022 Corporate
- Filing of Patent Infringement Suit against AstraZeneca K.K.
-
- Feb.28.2022 R & D
- Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%
-
- Feb.28.2022 R & D
- Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable, Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1 Expression ≥ 1%
-
- Feb.28.2022 R & D
- Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%
-
- Feb.28.2022 Management / Finance
- Ono Announces Status and Completion of Acquisition of Own Shares
-
- Feb.24.2022 Corporate
- Notice regarding Collaboration between Ono and Maruha Nichiro in the Field of Health Foods
-
- Feb.21.2022 R & D
- Velexbru® Tablet 80 mg, a BTK inhibitor, Approved in Taiwan for the Treatment of Recurrent or Refractory B-cell Primary Central Nervous System Lymphoma
-
- Feb.15.2022 R & D
- Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
-
- Feb.15.2022 R & D
- Opdivo® Intravenous Infusion Approved in South Korea for Two Adjuvant Treatments and Three Combination Treatments
-
- Feb.03.2022 R & D
- ONO and Bristol Myers Squibb Sign Outsourcing Agreement with PRiME-R on Clinical Research of Opdivo® in Patients with Gastric Cancer, utilizing CyberOncology® in Japan
-
- Feb.01.2022 Management / Finance
- Ono Announces Status of Acquisition of Own Shares
-
- Jan.31.2022 Management / Finance
- Announcement on Financial Results for FY2021 3Q
-
- Jan.28.2022 R & D
- Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination with Azacitidine
-
- Jan.25.2022 R & D
- Opdivo® Intravenous Infusion Approved for the First-line Treatment of Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer in Combination with Bevacizumab and Chemotherapy in Taiwan
-
- Jan.17.2022 Licensing
- Ono Expands Drug Discovery Collaboration with Neurimmune AG in the Field of Neurodegenerative Diseases
-
- Jan.05.2022 R & D
- Opdivo® Intravenous Infusion Approved for the Adjuvant Treatment of Esophageal Cancer or Gastroesophageal Junction Cancer in Taiwan
-
- Jan.05.2022 Management / Finance
- Ono Announces Status of Acquisition of Own Shares